PDX Model Cohort
Renal Cell Carcinoma & Kidney Cancer PDX Models
An extensive bank of Renal Cell Carcinoma PDX models & Kidney Cancer PDX Models directly established from late stage, metastatic tumors, and pretreated patient tumors available for drug development research.
Summary
Champions Oncology offers 29* clinically relevant Renal Cell Carcinoma PDX models & Kidney Cancer PDX Models models derived from patients with late-stage, metastatic, and heavily pre-treated disease, providing a rare and valuable resource for oncology drug development. Many of these models are extensively characterized through Next Generation Sequencing—36* with Whole Exome Sequencing (WES), 27* with RNA-seq, and 27* with both—along with in vivo drug response data, enabling robust biomarker analysis for response and non-response within this indication. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Renal Cell Carcinoma PDX models & Kidney Cancer PDX Model cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to one of the largest bank of Renal Cell Carcinoma & Kidney Cancer PDX models with clinically relevant molecular and pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with an array of advanced treatments, from monoclonal antibodies to targeted inhibitors in combination.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses